Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10555261			
Filing Date			2005-11-01			
First Named Inventor CHRIS		CHR	STINA RENDERS			
	Art Unit		2873			
	Examiner Name	DAVI	N. SPECTOR			
	Attorney Docket Numb	er	NI 030550			

Examiner Cite No Patent Number Kind Code1 Issue Date Name of Pater of cited Docum		entee or Applicant iment	Releva		Lines where							
	1	4030813		1977-06-02 KOHASHI ET AL								
	2 4384761 1983-05-24 BRADY ET AL											
	3	5541776		1996-07-3	90	KABAYASHI E	ET AL					
If you wis	h to a	dd additional U.S. Pater	ent citation information please click the Add butt				Add button.		Add		_	
			U.S.P	ATENT A	PPLK	CATION PUB	LICATIONS		Remove		_	
		Kind Code ¹	ind Publication Date		Name of Patentee or Applicant Rele		Releva	ges,Columns,Lines where levant Passages or Relevant jures Appear				
	1	20010017985 A1 2001-08-30 TSUBOLET AL										
	2	20030048541	A1	2003-03-1	13	KROUPENKIN	NE ET AL					
If you wis	h to a	dd additional U.S. Publi:	shed Ap	plication o	itation	n information p	please click the Ad	d button	Add		_	
				FOREIGN	N PAT	ENT DOCUM	IENTS		Remove			
Examiner Cite Foreign Document Country Kind Printial* No Number Code2 i Code4 C			Publication	Name of Patente Applicant of cited	e or	Pages,Coli where Rele Passages		т-				

U.S. PATENTS

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10555261		
Filing Date		2005-11-01		
First Named Inventor CHRI		STINA RENDERS		
Art Unit		2873		
Examiner Name DAVID		D N. SPECTOR		
Attornov Docket Number		NI 030550		

	1	2003069380	wo	A1	2003-08-02	KPENV		
	2	2004027489	wo	A1	2004-04-01	KPENV		
	3	2004027490	wo	A1	2004-04-01	KPENV		
	4	2004038480	wo	A1	2004-05-06	KPENV		
If you wis	h to a	dd additional Foreign P	atent Document	citation	information pl	ease click the Add buttor		
			NON-PATER	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	Cite No		nal, serial, symp	osium,	catalog, etc), o	the article (when appropriate, pages(s), volume-is		Ţ5
	1 ISR PCT/IB2004/050569							
	1	ISR: PCT/IB2004/05056	8					
	2	ISR: PCT/IB2004/05056 WRITTEN OPINION: PC						
		WRITTEN OPINION: PO	CT/IB2004/050568	NS CON		IN EXTERNAL VOLTAGE: P 159-163, XP00Z285977		
If you wis	2	WRITTEN OPINION: PO B.BERGE ET AL, "VARI ELECTROWEITING", T	CT/IB2004/050568 ABLE FOCAL LET THE EUROPEAN F	NS CON PHYSIC	AL JOURNAL, F			
If you wis	2	WRITTEN OPINION: PO B.BERGE ET AL, "VARI ELECTROWEITING", T	CT/IB2004/050568 ABLE FOCAL LETHE EUROPEAN I	NS CON PHYSIC	AL JOURNAL, F	P 159-163, XP002285977 on please click the Add I		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Application Number		10555261	
	Filing Date		2005-11-01	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	First Named Inventor CHRI		ISTINA RENDERS	
	Art Unit		2873	
	Examiner Name DAVI		ID N. SPECTOR	
	Attorney Docket Number		NL030550	

See Kind Code of USPTO Petert Documents at invest, ISETIG.ODV or MEPF 961.04. It better dots that issued the document, by the lockletic code (WIPO Standard S13.) If the planeses patient document, the includation of the parent for the grant or the representation precised the sensal number of the patient for sensal for some of the parent for the patient for patient

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10555261			
Filing Date		2005-11-01			
First Named Inventor CHRI		STINA RENDERS			
Art Unit		2873			
Examiner Name DAVI		N. SPECTOR			
Attorney Docket Numb	er	NL030550			

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication
from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ▼ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

on the agradate.							
Signature	/MICHAEL E. BELK/	Date (YYYY-MM-DD)	2007-08-21				
Name/Print	MICHAEL E RELK	Registration Number	33357				

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 37 CFR.

1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenski Office, V.S. operatment of Comments of Office, V.S. Agrandin, V.S. 2231-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 80x 1450, Alexandria, V.A. 22313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.